WVE / Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological Indications

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal

Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 tri more_horizontal

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor R more_horizontal

Wave Life Sciences (WVE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to lo more_horizontal

Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade) more_horizontal

Wave Life Sciences (WVE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.6 more_horizontal

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the num more_horizontal

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy more_horizontal